UBT251 Triple Agonist Delivers 19.7% Weight Loss in Phase 2
Novo Nordisk and United Laboratories' new triple agonist achieved 19.7% weight loss in 24 weeks vs 2.0% placebo, intensifying competition with retatrutide.
#Ubt251
1 story
1 story
Novo Nordisk and United Laboratories' new triple agonist achieved 19.7% weight loss in 24 weeks vs 2.0% placebo, intensifying competition with retatrutide.